A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising.
Saved in:
| Title: | A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. |
|---|---|
| Authors: | Frosch DL (AUTHOR), Grande D (AUTHOR), Tarn DM (AUTHOR), Kravitz RL (AUTHOR) |
| Source: | American Journal of Public Health. Jan2010, Vol. 100 Issue 1, p24-32. 9p. |
| Subjects: | Direct-to-consumer prescription drug advertising, Drug advertising, Health policy, Pharmaceutical industry, Consumer education, United States politics & government, 1989-, Ethics |
| Geographic Terms: | United States |
| Abstract: | Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in population-level health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertising. [ABSTRACT FROM AUTHOR] |
| Copyright of American Journal of Public Health is the property of American Public Health Association and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in population-level health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertising. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00900036 |
| DOI: | 10.2105/AJPH.2008.153767 |
